Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atumelnant - Crinetics Pharmaceuticals

Next Previous
Drug Profile

Atumelnant - Crinetics Pharmaceuticals

Alternative Names: CRN 04894

Latest Information Update: 25 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crinetics Pharmaceuticals
  • Class Amides; Antineoplastics; Antisecretories; Benzene derivatives; Cyclobutanes; Ethers; Fluorocarbons; Ketones; Piperazines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Melanocortin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Congenital adrenal hyperplasia; Cushing syndrome
  • No development reported Ectopic ACTH syndrome

Most Recent Events

  • 21 Aug 2025 Atumelnant receives Orphan Drug status for Congenital adrenal hyperplasia in the US
  • 07 Aug 2025 Crinetics pharmaceuticals plans phase II/III clinical trial for Cushing’s disease in 1H 2026
  • 08 May 2025 Crinetics Pharmaceuticals plans the phase III CALM-CAH trial for Congenital adrenal hyperplasia (In adults) (PO), in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top